Real-World data reveals treatment patterns for advanced prostate cancer

NCT ID NCT06072196

Completed Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study examined how long men with metastatic castration-sensitive prostate cancer take newer hormonal therapies like abiraterone, apalutamide, and enzalutamide. Researchers analyzed Medicare claims data from over 3,000 men aged 65 and older. The goal was to describe real-world treatment duration, not to test a new drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: abiraterone, apalutamide, enzalutamide
What this could lead to: If successful, this study could help doctors understand how long patients typically stay on these treatments, guiding better care decisions.
What could go wrong: This is an observational study using insurance claims, not a controlled trial. It cannot prove cause and effect, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATIC NEOPLASMS

Contacts and locations

Locations

Pfizer, Inc

New York, New York, 10001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.